Last updated: February 14, 2026
Overview of the Drug
The National Drug Code (NDC) 00173-0758 refers to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody conjugate approved by the FDA in August 2020. It targets BCMA (B-cell maturation antigen) and is used for relapsed or refractory multiple myeloma (RRMM) after at least four prior therapies. The drug's mechanism involves delivering a toxic payload directly to cancer cells, leading to cell apoptosis.
Market Landscape
The multiple myeloma (MM) treatment market is highly competitive, with over 30 approved therapies as of 2023, including CAR T-cell therapies, bispecific antibodies, and proteasome inhibitors. Blenrep's approval positions it within a niche of targeted therapies for previously treated MM.
Key competitors include:
- Carfilzomib (Kyprolis)
- Pomalidomide (Pomalyst)
- Selinexor (Xpovio)
- Idecabtagene vicleucel (Abecma)
- Luspatercept (Reblozyl)
Blenrep faces competition from both multiple drug classes, with varied efficacy, side effect profiles, and administration routes.
Market Size and Penetration
The multiple myeloma market in the U.S. was valued at approximately $8 billion in 2022, with a compound annual growth rate (CAGR) of 10% from 2020 to 2022, driven by increased diagnosis and therapy advancements.
Estimated market penetration of Blenrep:
- In Year 1 post-launch (2021): approximates 5% of eligible patients.
- By Year 3 (2023): could reach 15%, assuming steady uptake based on Phase 3 trial data and physician familiarity.
- Estimated eligible patient pool: 30,000 in the U.S. (based on incidence rates and treatment eligibility criteria).
Total patient treatment projections:
| Year |
Patients (U.S.) |
Market Share |
Prescriptions |
Annual Revenue Estimate (USD) |
| 2021 |
1,500 |
5% |
7,500 |
$315 million (assuming avg price $42,000) |
| 2022 |
4,500 |
10% |
22,500 |
$945 million |
| 2023 |
4,500 |
15% |
33,750 |
$1.42 billion |
Price Projections
Initial Pricing: The wholesale acquisition cost (WAC) of Blenrep was approximately $12,000 per vial at launch, with a typical dose being 2.5 mg/kg administered quarterly. This leads to an approximate per-treatment cost of $42,000, similar to other monoclonal antibody-based therapies in oncology.
Price Trends over Time:
- Stability or slight decrease expected with increased competition and biosimilar entry from other BCMA-targeted agents.
- Volume-driven revenue: If market share increases based on physician acceptance and expanded indications, total revenue could grow despite price pressures.
Potential Price Adjustments:
- A 5-10% decrease in price over five years, driven by biosimilar competition and market saturation.
- Alternatively, price adjustments may vary by payer negotiations, with payers pushing for discounts or formulary placement favors.
Pricing Compared to Similar Therapies
| Drug |
WAC (USD) |
Indication |
Administration |
Key Features |
| Blenrep |
~$42,000 per treatment |
RRMM |
IV, quarterly |
ADC targeting BCMA |
| Abecma |
~$400,000 per CAR T |
RRMM |
IV, single infusion |
Personalized cell therapy |
| Selinexor |
~$12,000 per month |
RRMM |
Oral, weekly |
Selective export inhibitor |
Blenrep's per-treatment cost remains in the mid-range among RRMM therapies, balancing between high-cost cell therapies and oral agents.
Regulatory and Reimbursement Outlook
- Reimbursement largely based on the drug's demonstrated efficacy in heavily pre-treated populations.
- Payors shift toward value-based agreements, potentially influencing drug price over time.
- Expanded indications (e.g., earlier lines of therapy) might justify higher prices but face regulatory hurdles.
Implications of Market Dynamics
- High unmet demand in relapsed/refractory settings supports steady demand.
- Competition from new BCMA-targeted agents (e.g., CAR T, bispecifics) likely to impact market share.
- Biosimilar development or alternative conjugates could exert downward pressure.
Summary
Blenrep is positioned as a targeted therapy for relapsed/refractory multiple myeloma, with an initial price around $42,000 per treatment. Market penetration primarily depends on physician adoption, competing therapies, and emerging biosimilars. Revenue estimations project growth aligned with increased treatment rates but face potential pricing pressure.
Key Takeaways
- The drug's estimated annual U.S. sales could reach $1.4 billion by 2023 at 15% market share.
- Pricing may decline 5-10% over five years due to biosimilar competition and payer negotiations.
- Market dynamics are influenced by the proliferation of BCMA-targeted therapies, including CAR T and bispecific antibodies.
- Implementation of value-based pricing models could affect future pricing strategies.
- Expansion into earlier treatment lines remains a potential for growth but requires regulatory approval and clinical validation.
Frequently Asked Questions
1. What is the main competition for Blenrep in multiple myeloma?
CAR T-cell therapies like Abecma and Bispecific antibodies are significant competitors, offering potentially higher efficacy but at higher costs and with different administration complexities.
2. How might biosimilars impact the drug’s price?
Biosimilar entries could lead to a 10-20% reduction in price over the next five years, depending on market acceptance and regulatory approvals.
3. What factors influence the drug’s market penetration?
Physician familiarity, clinical efficacy, safety profile, reimbursement policies, and competition all play roles.
4. Are there strategic opportunities to expand the drug’s use?
Yes. Clinical trials exploring earlier lines of treatment or combination therapies could broaden its indications, potentially increasing market size.
5. What regulatory challenges could affect future pricing?
Thorough demonstration of value through efficacy and safety data, alongside payer negotiations, influences reimbursement and pricing.
References
[1] IQVIA. "U.S. Oncology Market Reports 2022."
[2] FDA. "Blenrep (belantamab mafodotin-blmf) Approval Letter," August 2020.
[3] EvaluatePharma. "World Market Outlook: Multiple Myeloma 2022."
[4] Amgen. "Blenrep Product Information."
